MIRA vs. NBRV, CASI, NXTC, OCUP, CLNN, EGRX, HCWB, AADI, DARE, and NRXP
Should you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Nabriva Therapeutics (NBRV), CASI Pharmaceuticals (CASI), NextCure (NXTC), Ocuphire Pharma (OCUP), Clene (CLNN), Eagle Pharmaceuticals (EGRX), HCW Biologics (HCWB), Aadi Bioscience (AADI), Daré Bioscience (DARE), and NRx Pharmaceuticals (NRXP). These companies are all part of the "pharmaceutical preparations" industry.
Nabriva Therapeutics (NASDAQ:NBRV) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.
0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
MIRA Pharmaceuticals has a net margin of 0.00% compared to MIRA Pharmaceuticals' net margin of -148.11%. Nabriva Therapeutics' return on equity of -293.51% beat MIRA Pharmaceuticals' return on equity.
In the previous week, MIRA Pharmaceuticals had 2 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 3 mentions for MIRA Pharmaceuticals and 1 mentions for Nabriva Therapeutics. Nabriva Therapeutics' average media sentiment score of 0.72 beat MIRA Pharmaceuticals' score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.
MIRA Pharmaceuticals has lower revenue, but higher earnings than Nabriva Therapeutics. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
Nabriva Therapeutics received 393 more outperform votes than MIRA Pharmaceuticals when rated by MarketBeat users.
Summary
MIRA Pharmaceuticals beats Nabriva Therapeutics on 7 of the 12 factors compared between the two stocks.
Get MIRA Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MIRA Pharmaceuticals Competitors List
Related Companies and Tools
